Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Ligumsky, Hagai; Dor, Herut; Etan, Tal; Golomb, Inbal; Nikolaevski‐Berlin, Alla; Greenberg, Inbal; Halperin, Tami; Angel, Yoel; Henig, Oryan; Spitzer, Avishay; Slobodkin, Marina; Wolf, Ido

doi:10.1016/s1470-2045(21)00715-4

Cited by 32 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cohort study confirms a favorable safety profile of the third dose of tozinameran in a broad sample of cancer patients receiving active treatments. While residual confounding may still be present, comparative evaluation within the PSM population suggests improved immunogenicity of booster dosing, independent of types and timing of systemic therapies and consistent with similar studies that employed the same serologic testing methodology 4 , 5 . Although longer follow-up is required, the effects of booster vaccine dosing appear to translate into a reduced risk of infection during intense SARS-CoV-2 VOC outbreaks.…”

supporting

confidence: 57%

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

et al. 2022

View full text Add to dashboard Cite

supporting

confidence: 57%

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

et al. 2022

View full text Add to dashboard Cite

“…A total of 3173 articles from PubMed (1577), the Cochrane Library (191), Embase (539), medRxiv (734), Wanfang (68) and CNKI (64) were initially included. After screening 2578 titles and abstracts and 83 full-text articles, 28 studies [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ] provided data on nine combinations of COVID-19 booster vaccinations (including homologous immunization and heterologous immunization), and 5870 subjects met the eligibility criteria ( Figure 1 ). The study populations mainly included the general population, health care workers and residents of a care home, which were all without history of laboratory-confirmed COVID-19.…”

Section: Resultsmentioning

confidence: 99%

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis

Cheng

Peng

et al. 2022

Vaccines

View full text Add to dashboard Cite

A prime–boost strategy of COVID-19 vaccines brings hope to limit the spread of SARS-CoV-2, while the immunogenicity of the vaccines is waning over time. Whether a booster dose of vaccine is needed has become a widely controversial issue. However, no published meta-analysis has focused on the issue. Therefore, this study assessed the immunogenicity and safety of the different combinations of prime–boost vaccinations. Electronic databases including PubMed, the Cochrane Library, Embase, medRxiv, Wanfang and CNKI were used to retrieve the original studies. A total of 28 studies, 9 combinations of prime–boost vaccinations and 5870 subjects were included in the meta-analysis, and random effect models were used to estimate pooled immunogenicity and safety. The immunity against COVID-19 after the prime vaccination waned over time, especially in the populations primed with inactivated vaccines, in which the seropositive rate of antibodies was only 28% (95% CI: 17–40%). Booster vaccination could significantly increase the antibody responses, and heterologous immunization was more effective than homologous immunization (neutralization titers: 1.65 vs. 1.27; anti-RBD IgG: 1.85 vs. 1.15); in particular, the combination of inactivated–mRNA vaccines had the highest antibody responses (neutralization titers: MRAW = 3.64, 95% CI: 3.54–3.74; anti-RBD IgG: 3.73, 95% CI: 3.59–3.87). Moreover, compared with the initial two doses of vaccines, a booster dose did not induce additional or severe adverse events. The administration of the booster dose effectively recalled specific immune responses to SARS-CoV-2 and increased antibody levels, especially in heterologous immunization. Considering the long-term immunogenicity and vaccine equity, we suggest that now, only individuals primed with inactivated vaccines require a booster dose.

show abstract

“…Data from initial studies suggest that the waning of the immune response seen in the months following vaccination against COVID-19 is comparable among patients with cancer and in the general population 139 , possibly with more pronounced waning in patients with cancer 140 . In the light of these waning antibody responses and a greater proportion of patients with cancer already being at risk of inferior immune responses to vaccination, these patients have been globally prioritized to receive booster vaccination.…”

Section: Vaccination In Patients With Cancermentioning

confidence: 99%

“…Booster vaccination increases the antibody responses of patients with solid tumours 101 , 143 even in those vaccinated while also receiving treatment 140 . The level of benefit in these patients appears to be high even in those who were seronegative after the second vaccine dose 144 .…”

Section: Vaccination In Patients With Cancermentioning

confidence: 99%

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

et al. 2022

View full text Add to dashboard Cite

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

show abstract

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Cited by 32 publications

References 8 publications

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Contact Info

Product

Resources

About